MeiraGTx
MeiraGTx
MGTX
NASDAQ
7.99
USD
24.65%
About
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases.
Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 131.2K |
| Three Month Average Volume | 4.0M |
| High Low | |
| Fifty-Two Week High | 7.6 USD |
| Fifty-Two Week Low | 3.49 USD |
| Fifty-Two Week High Date | 26 Dec 2023 |
| Fifty-Two Week Low Date | 25 Oct 2023 |
| Price and Volume | |
| Current Price | 4.07 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -19.40% |
| Thirteen Week Relative Price Change | -22.39% |
| Twenty-Six Week Relative Price Change | -42.25% |
| Fifty-Two Week Relative Price Change | -48.36% |
| Year-to-Date Relative Price Change | -51.04% |
| Price Change | |
| One Day Price Change | -2.63% |
| Thirteen Week Price Change | -16.94% |
| Twenty-Six Week Price Change | -36.51% |
| Five Day Price Change | -2.40% |
| Fifty-Two Week Price Change | -35.29% |
| Year-to-Date Price Change | -42.02% |
| Month-to-Date Price Change | -22.18% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.17256 USD |
| Book Value Per Share (Most Recent Quarter) | 1.23738 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.15498 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.2224 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.48215 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.24815 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.12981 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.48756 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.49406 USD |
| Normalized (Last Fiscal Year) | -2.42688 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.48756 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.49406 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.48756 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.49406 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.03717 USD |
| Cash Per Share (Most Recent Quarter) | 1.54557 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.24449 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.26667 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.67426 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -390 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,290 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,146.81% |
| Pretax Margin (Last Fiscal Year) | -599.47% |
| Pretax Margin (5 Year) | -420.70% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -977.82% |
| Operating Margin (Trailing Twelve Months) | -2,083.19% |
| Operating Margin (5 Year) | -463.24% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -599.47% |
| Net Profit Margin (Trailing Twelve Months) | -1,146.81% |
| Net Profit Margin (5 Year) | -420.70% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -6.00% |
| Tangible Book Value (5 Year) | 11.08% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -92.03% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 26.87% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -3.43% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 12.37% |
| Total Debt (5 Year) | 361.90% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -41.32% |
| EPS Change (Trailing Twelve Months) | 41.85% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -27,309,000 |
| Net Debt (Last Fiscal Year) | -57,447,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 22 |
| Price to Sales (Trailing Twelve Months) | 39 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 52 |
| Long Term Debt to Equity (Most Recent Quarter) | 91 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -125,539,000 |
| Free Cash Flow (Trailing Twelve Months) | -104,759,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -91 |
| Net Interest Coverage (Trailing Twelve Months) | -23 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 52 |
| Total Debt to Equity (Most Recent Quarter) | 91 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -26.06% |
| Return on Assets (Trailing Twelve Months) | -32.29% |
| Return on Assets (5 Year) | -26.40% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -65.67% |
| Return on Equity (Trailing Twelve Months) | -91.51% |
| Return on Equity (5 Year) | -48.20% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.89% |
| Return on Investment (Trailing Twelve Months) | -40.66% |
| Return on Investment (5 Year) | -32.66% |